Olorinab (APD371), a peripherally restricted, highly selective, full agonist of the cannabinoid receptor type 2 (CB2), reduces visceral hypersensitivity in animal models

被引：0
|
作者：
Castro, J. [1 ]
Maddern, J. [1 ]
Garcia-Caraballo, S. [1 ]
Lumsden, A. [1 ]
Lindstrom, B. [2 ]
Adams, J. [2 ]
Brierley, S. M. [1 ]
机构：
[1] Flinders Univ S Australia, Visceral Pain Res Grp, SAHMRI, Adelaide, SA, Australia
[2] Arena Pharmaceut Inc, San Diego, CA USA
来源：
NEUROGASTROENTEROLOGY AND MOTILITY | 2019年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
15
引用
收藏
页数：2
相关论文
共 50 条
  • [31] ZYKR1, a novel, potent, and peripherally selective kappa opioid receptor agonist reduces visceral pain and pruritus in animal models
    Jain, Mukul R.
    Patel, Rakesh B.
    Prajapati, Kanaiyalal D.
    Vyas, Purvi
    Bandyopadhyay, Debdutta
    Prajapati, Vijay
    Bahekar, Rajesh
    Patel, Prakash N.
    Kawade, Harish M.
    Kokare, Dadasaheb M.
    Pawar, Vishwanath
    Desai, Ranjit
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2022, 924
  • [32] The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain
    Jaggar, SI
    Hasnie, FS
    Sellaturay, S
    Rice, ASC
    PAIN, 1998, 76 (1-2) : 189 - 199
  • [33] Ligand-steered modeling of the cannabinoid receptor 2: Successful applications to rationalize SAR data of selective CB2 inverse agonist and agonist compounds
    Phatak, Sharangdhar S.
    Diaz, Philippe
    Xu, Jijun
    Astruc-Diaz, Fanny
    Naguib, Mohammed
    Cavasotto, Claudio N.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 240
  • [34] A cannabinoid type 2 (CB2) receptor agonist augments NOS-dependent responses of cerebral arterioles during type 1 diabetes
    Van Hove, Lauren
    Kim, Kirsten R.
    Arrick, Denise M.
    Mayhan, William G.
    MICROVASCULAR RESEARCH, 2021, 133
  • [35] A selective cannabinoid CB2 receptor agonist decreases infarct volume in a mouse middle cerebral artery occlusion/reperfusion model
    Zhang, M
    Martin, BR
    Baron, E
    Adler, MW
    Jallo, J
    Tuma, RF
    FASEB JOURNAL, 2006, 20 (05): : A1157 - A1157
  • [36] Anti-Inflammatory Activity of a CB2 Selective Cannabinoid Receptor Agonist: Signaling and Cytokines Release in Blood Mononuclear Cells
    Capozzi, Antonella
    Caissutti, Daniela
    Mattei, Vincenzo
    Gado, Francesca
    Martellucci, Stefano
    Longo, Agostina
    Recalchi, Serena
    Manganelli, Valeria
    Riitano, Gloria
    Garofalo, Tina
    Sorice, Maurizio
    Manera, Clementina
    Misasi, Roberta
    MOLECULES, 2022, 27 (01):
  • [37] Anti-Proliferative Properties and Proapoptotic Function of New CB2 Selective Cannabinoid Receptor Agonist in Jurkat Leukemia Cells
    Capozzi, Antonella
    Mattei, Vincenzo
    Martellucci, Stefano
    Manganelli, Valeria
    Saccomanni, Giuseppe
    Garofalo, Tina
    Sorice, Maurizio
    Manera, Clementina
    Misasi, Roberta
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (07)
  • [38] CB2 cannabinoid receptor agonist, JWH-015, triggers apoptosis in immune cells: Potential role for CB2-selective ligands as immunosuppressive agents
    Lombard, Catherine
    Nagarkatti, Mitzi
    Nagarkatti, Prakash
    CLINICAL IMMUNOLOGY, 2007, 122 (03) : 259 - 270
  • [39] A Cannabinoid CB2 receptor agonist attenuates experimental autoimmune encephalomyelitis (EAE) and reduces MOG-specific T cell proliferation
    Zhang, Ming
    Yen, Jui-Hung
    Kharullina, Tanzilya
    Ganea, Doina
    Tuma, Ronald F.
    FASEB JOURNAL, 2007, 21 (06): : A1393 - A1393
  • [40] Potent immunomodulatory activity of a highly selective cannabinoid CB2 agonist on immune cells from healthy subjects and patients with multiple sclerosis
    Annunziata, Pasquale
    Cioni, Chiara
    Mugnaini, Claudia
    Corelli, Federico
    JOURNAL OF NEUROIMMUNOLOGY, 2017, 303 : 66 - 74
12345